SCYNEXIS, Inc. to Participate in the 2017 BIO International Convention
JERSEY CITY, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer, will participate in a panel at the 2017 BIO International Conference at the San Diego Convention Center on Tuesday, June 20, 2017, at 4:15 p.m. PT. The panel, “Antifungus Among Us: Recognizing Vulnerability and Opportunity with the Next-Generation of Antifungals,” will focus on the growing global health epidemic and highlight the urgent needs and opportunities in the antifungal space.
SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company's lead product candidate, SCY-078, is the first representative of a novel intravenous and oral triterpenoid antifungal family and is in Phase 2 clinical development for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 email@example.com Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 firstname.lastname@example.org
Released June 13, 2017